Table 3: Distribution of KIR and HLA ligands in HPV patients and controls.

KIR and HLA ligandsHPV patientsControls
% %

2DL1-C24667.657867.24
2DL1 without C22232.353832.75
2DL2-C12880.04378.18
2DL2 without C1720.01221.81
2DL3-C15485.718783.65
2DL3 without C1914.291716.34
3DL1-Bw44467.697366.97
3DL1 without Bw42132.313633.02
2DS1-C22273.333060.00
2DS1 without C2826.672040.00
2DS2-C13081.084578.94
2DS2 without C1718.921221.05
3DS1-Bw42167.743062.50
3DS1 without Bw41032.261837.50

Bw4: HLA-A*23, 24, and 32; HLA-B*08, 13, 27, 37, 44, 51, 52, 53, 57, and 58.
Group C1: HLA-C*01, 03, 07, 08, 12, 14, and 16.
Group C2: HLA-C*02, 04, 05, 06, 07, 15, 17, and 18.
Difference was not observed ( ).